Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

The United States has begun distributing a groundbreaking HIV-prevention treatment to two African nations, marking a ...